Protalix BioTherapeutics Seeks Multiple Collaborative Partnerships To Complement Core Platform JERUSALEM (dpa-AFX) - Protalix BioTherapeutics, Inc. (PLX), a biopharmaceutical company, said Wednesday that its President and Chief Executive Officer Dror Bashan has sent an annual letter to the company's shareholders and the investment community. In the 2020 letter to shareholders, Bashan said that together with Chiesi Global Rare Diseases, the company's development and commercialization partner, it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration or FDA for PRX-102, for the treatment of adult patients with Fabry disease. The company is looking forward to commercializing PRX-102 assuming the anticipated approval of the BLA in the second half of 2021.